JP2018532407A5 - - Google Patents

Download PDF

Info

Publication number
JP2018532407A5
JP2018532407A5 JP2018520157A JP2018520157A JP2018532407A5 JP 2018532407 A5 JP2018532407 A5 JP 2018532407A5 JP 2018520157 A JP2018520157 A JP 2018520157A JP 2018520157 A JP2018520157 A JP 2018520157A JP 2018532407 A5 JP2018532407 A5 JP 2018532407A5
Authority
JP
Japan
Prior art keywords
nucleic acid
chimeric receptor
endodomain
receptor
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018520157A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018532407A (ja
JP7082046B2 (ja
Filing date
Publication date
Priority claimed from GBGB1518816.2A external-priority patent/GB201518816D0/en
Application filed filed Critical
Publication of JP2018532407A publication Critical patent/JP2018532407A/ja
Publication of JP2018532407A5 publication Critical patent/JP2018532407A5/ja
Priority to JP2022007006A priority Critical patent/JP2022058681A/ja
Application granted granted Critical
Publication of JP7082046B2 publication Critical patent/JP7082046B2/ja
Priority to JP2023222448A priority patent/JP2024024014A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018520157A 2015-10-23 2016-10-21 受容体 Active JP7082046B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022007006A JP2022058681A (ja) 2015-10-23 2022-01-20 受容体
JP2023222448A JP2024024014A (ja) 2015-10-23 2023-12-28 受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1518816.2A GB201518816D0 (en) 2015-10-23 2015-10-23 Receptor
GB1518816.2 2015-10-23
PCT/GB2016/053290 WO2017068360A1 (en) 2015-10-23 2016-10-21 Receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022007006A Division JP2022058681A (ja) 2015-10-23 2022-01-20 受容体

Publications (3)

Publication Number Publication Date
JP2018532407A JP2018532407A (ja) 2018-11-08
JP2018532407A5 true JP2018532407A5 (enExample) 2019-10-03
JP7082046B2 JP7082046B2 (ja) 2022-06-07

Family

ID=55130152

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018520157A Active JP7082046B2 (ja) 2015-10-23 2016-10-21 受容体
JP2022007006A Withdrawn JP2022058681A (ja) 2015-10-23 2022-01-20 受容体
JP2023222448A Pending JP2024024014A (ja) 2015-10-23 2023-12-28 受容体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022007006A Withdrawn JP2022058681A (ja) 2015-10-23 2022-01-20 受容体
JP2023222448A Pending JP2024024014A (ja) 2015-10-23 2023-12-28 受容体

Country Status (9)

Country Link
US (2) US11242377B2 (enExample)
EP (1) EP3364998A1 (enExample)
JP (3) JP7082046B2 (enExample)
CN (1) CN108135988A (enExample)
AU (1) AU2016342560B2 (enExample)
CA (1) CA3001792A1 (enExample)
GB (1) GB201518816D0 (enExample)
HK (1) HK1252163A1 (enExample)
WO (1) WO2017068360A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
HRP20240357T1 (hr) * 2014-12-24 2024-06-07 Autolus Limited Stanica
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518816D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Receptor
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
CA3045667A1 (en) 2016-12-13 2018-06-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
AU2019218729B2 (en) 2018-02-06 2025-12-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Car t細胞療法のための配列決定法
AU2019227979B2 (en) 2018-03-02 2024-09-05 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
CA3091490A1 (en) 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Rapamycin resistant cells
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
GB201814203D0 (en) * 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
CN111378046B (zh) * 2018-12-27 2024-03-15 上海细胞治疗集团有限公司 一种免疫效应细胞转换受体
US20230348556A1 (en) * 2019-02-21 2023-11-02 Arbele Limited Artificial immunosurveillance chimeric antigen receptor and cells expressing the same
IL328846A (en) 2019-03-01 2026-08-01 Allogene Therapeutics Inc Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases
IL285941B1 (en) 2019-03-01 2026-08-01 Allogene Therapeutics Inc Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN
BR112022003553A2 (pt) 2019-08-30 2022-05-24 Allogene Therapeutics Inc Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta
US20220401537A1 (en) * 2019-09-16 2022-12-22 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
IL295063A (en) 2020-02-04 2022-09-01 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Chimeric antigen receptors (car) against dinitrophenol
PE20221757A1 (es) 2020-02-24 2022-11-11 Allogene Therapeutics Inc Celulas t con car de bcma con actividades mejoradas
CN111269326A (zh) * 2020-02-28 2020-06-12 南京北恒生物科技有限公司 新型嵌合抗原受体及其用途
JP7557042B2 (ja) * 2020-08-19 2024-09-26 山東博安生物技術股▲ふん▼有限公司 ステルスキメラ抗原受容体及び正常細胞への細胞毒性の低減におけるその用途
US20240082306A1 (en) * 2021-02-03 2024-03-14 Bioheng Therapeutics Limited Novel chimeric antigen receptor and use thereof
JP2026507781A (ja) 2023-01-23 2026-03-06 メディツィニシェ ホゥーシュル ハノーファー キメラ抗原受容体
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
CN120787258A (zh) 2023-02-07 2025-10-14 圭尔医疗有限公司 Treg细胞培养方法
WO2024175805A1 (en) 2023-02-24 2024-08-29 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194355A1 (en) 2023-03-20 2024-09-26 Medizinische Hochschule Hannover Chimeric antigen receptor
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用
US20260176598A1 (en) 2024-07-04 2026-06-25 Quell Therapeutics Limited Expression construct
GB202411558D0 (en) 2024-08-06 2024-09-18 Quell Therapeutics Ltd Culture method

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9809658D0 (en) 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
PT2126054T (pt) 2007-01-31 2016-10-12 Yeda Res & Dev Células t reguladoras geneticamente modificadas, redirecionadas e sua utilização na supressão de doenças inflamatórias e autoimunitárias
EP2614143B1 (en) * 2010-09-08 2018-11-07 Baylor College Of Medicine Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
EP2694640B1 (en) 2011-04-08 2017-10-18 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
SG11201507026WA (en) 2013-02-06 2015-10-29 Anthrogenesis Corp Modified t lymphocytes having improved specificity
EP2970372B1 (en) 2013-03-15 2020-09-30 Celgene Corporation Modified t lymphocytes
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Cd33キメラ抗原受容体を使用する癌の処置
CA2974998C (en) 2015-02-12 2022-04-26 Takara Bio Inc. Chimeric antigen receptors
US11248058B2 (en) * 2015-02-19 2022-02-15 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
MA41962A (fr) 2015-04-23 2018-02-28 Baylor College Medicine Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
WO2016197108A1 (en) 2015-06-05 2016-12-08 Board Of Regents, The University Of Texas System Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518816D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Receptor

Similar Documents

Publication Publication Date Title
AU2018203687B2 (en) Improved methods for manufacturing adoptive cell therapies
RU2719030C2 (ru) Улучшенные композиции на основе t-клеток
KR102930430B1 (ko) 항-bcma 키메라 항원 수용체
JP2022173235A (ja) Bcma関連癌および自己免疫疾患の治療のための併用療法
RU2016124280A (ru) Клетка
JP2019150066A5 (enExample)
JP2018523484A5 (enExample)
JP2017537627A5 (enExample)
JP2020513754A5 (enExample)
CN107106670A (zh) 用于修饰的t细胞的方法和组合物
JP2021517473A (ja) Cd30+腫瘍の治療のためのcar−cd30t細胞
JP2016514462A5 (enExample)
RU2018111462A (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
JP2019535262A5 (enExample)
US12109235B2 (en) TGF-beta receptors and methods of use
HK1233928A1 (en) Improved methods for manufacturing adoptive cell therapies
HK1233928B (en) Improved methods for manufacturing adoptive cell therapies